• Mashup Score: 1

    Asthma exacerbations, oral corticosteroid use, and increased asthma severity are associated with adverse perinatal outcomes.1 Asthma biologics have transformed the management of severe asthma (SA), but the clinical trials that served as the basis for regulatory approvals for the biologics excluded pregnant women, and data on their safety and efficacy during pregnancy are limited. Here, we present a case series on the use of benralizumab, an IL-5 receptor antagonist, in pregnant women with SA. We obtained informed consent from all patients.

    Tweet Tweets with this article
    • In Current Issue! #Benralizumab #treatment of #severe #asthma in #pregnancy: A #case #series https://t.co/6ZKpjO3M3k https://t.co/BkXlCDm5fT

  • Mashup Score: 0

    Severe asthma affects about 10% of the population with asthma and is characterized by low lung function and a high count of blood leukocytes, mainly eosinophils. Various definitions are used in clinical practice and in the literature to identify asthma remission: clinical remission, inflammatory remission, and complete remission. This work highlights a consensus for asthma remission using a Delphi method. In the context of the Severe Asthma Network Italy, which accounts for 57 severe asthma centers and more than 2,200 patients, a board of six experts drafted a list of candidate statements in a questionnaire, which has been revised to minimize redundancies and ensure clear and consistent wording for the first round (R1) of the analysis.

    Tweet Tweets with this article
    • In Press! SANI definition of #Clinical #Remission in #Severe #Asthma: a Delphi consensus https://t.co/NI0qAxLVff

  • Mashup Score: 3

    The availability of biologic agents for patients with severe asthma has increased dramatically over the last several decades. The absence of direct head-to-head comparative data and relative lack of biomarkers to predict response can make it difficult to choose the right biologic medication for a given patient. Selecting a biologic agent for the pediatric population presents further challenges due to more limited approved biologic agents and fewer clinical trials in children. In addition, the outcome data that are currently available suggest that treatment responses for a given biologic may be different between adult and pediatric patients.

    Tweet Tweets with this article
    • In Press! #Controversies in #Allergy: Are #Biologic #Treatment #Responses in #Severe #Asthma the Same in #Adults and #Children? https://t.co/zLhlpkLQgn https://t.co/MeP7VrK23L

  • Mashup Score: 0

    Keratoconjunctivitis (KC) is a rare chronic inflammation of the ocular surface. The prevalence is less than 1 in 10,000 people in Europe. Two forms exist: vernal KC (VKC), which begins in childhood, and atopic KC (AKC), which occurs or persists into adulthood and is often associated with atopic dermatitis. Atopic comorbidities such as asthma, atopic dermatitis, allergic rhinitis, and food allergies are frequently associated.1,2

    Tweet Tweets with this article
    • In Press! #Omalizumab for #severe #allergic #keratoconjunctivitis: A #case series https://t.co/H9vUij9XX4 https://t.co/NR1NnUGt7y